Aura Biosciences Posts $0.29 GAAP Loss Per Share for Q3 2026

Aura Biosciences, Inc. posted a GAAP loss of $0.29 per share for the third quarter of 2026. Its cash, cash equivalents and marketable securities totaled $297.2 million as of Sept. 30. The company said it believes those resources are sufficient to fund operations into the first half of 2029. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.